Research Paper Volume 16, Issue 16 pp 11926—11938
Caffeic acid derivative MPMCA suppresses osteoclastogenesis and facilitates osteoclast apoptosis: implications for the treatment of bone loss disorders
- 1 Graduate Institute of Biomedical Sciences, China Medical University, Taichung, Taiwan
- 2 School of Chinese Medicine, China Medical University, Taichung, Taiwan
- 3 Department of Orthopedic Surgery, China Medical University Hospital, Taichung, Taiwan
- 4 Department of Sports Medicine, China Medical University, Taichung, Taiwan
- 5 Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, Taiwan
- 6 Chinese Medicine Research Center, China Medical University, Taichung, Taiwan
- 7 Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan
- 8 Department of Medical Laboratory Science and Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan
- 9 Department of Medical Research, China Medical University Hsinchu Hospital, Hsinchu, Taiwan
Received: March 13, 2024 Accepted: July 18, 2024 Published: August 26, 2024
https://doi.org/10.18632/aging.206067How to Cite
Copyright: © 2024 Thuong et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Osteoclast activity plays a crucial role in the pathological mechanisms of osteoporosis and bone remodeling. The treatment of these disorders involves the use of pharmacological medicines that work by inhibiting the activity of osteoclasts. Nevertheless, the prevalent and infrequent negative consequences of current antiresorptive and bone anabolic treatments pose significant drawbacks, hence restricting their prolonged administration in patients, particularly those who are elderly and/or suffer from many medical conditions. We are currently in the process of creating a new molecule called N-(4-methoxyphen) methyl caffeamide (MPMCA), which is a derivative of caffeic acid. This compound has shown potential in preventing the production of osteoclasts and causing existing osteoclasts to undergo cell apoptosis. Our investigation discovered that MPMCA hinders osteoclast function via suppressing the MAPK pathways. The expectation is that the findings of this study will stimulate the advancement of a novel approach to treating anti-resorption.